

REMARKS

The applicants have amended claim 1 to include pharmaceutically acceptable salts of ceterizine, levocetirizine, and efletirizine. Support for this amendment can be found, *inter alia*, on p. 2, ll. 30-31 of the specification.

Claim 1 has also been amended to change “preservative effects” to “bactericidal effect.” Support for this amendment can be found on page 2, ll. 20-25, of the specification.

Several new claims have been added. Support for claims 13-16 and 18-26 can be found throughout the application and, in particular, Examples 2 and 4. Support for claim 17 can be found on page 3, ll. 3-7.

The remaining amendments merely improve the grammar without changing the scope.

In response to the restriction requirement, the applicants elect the following species:

- (i) active substance: levocetirizine
- (ii) preservative: mixture of methyl parahydroxybenzoate and propyl parahydroxybenzoate
- (iii) presence of thimerosal: no (absent)
- (iv) presence of chlorhexidine acetate: no (absent)
- (v) presence of benzyalcohol: no (absent)
- (vi) presence of benzalkonium chloride: no (absent)/

Claims 1-5, 11, 12 read on the elected species, as do new claims 13-26.

If it is believed that a teleconference will advance prosecution, the examiner is encouraged to contact the undersigned as indicated below.

Date: March 6, 2008

Telephone: 312-913-0001
Facsimile: 312-913-0002

Respectfully submitted,

/Michael S. Greenfield/
Michael S. Greenfield
Registration No. 37,142

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, IL 60606